Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Exp Hematol Retrieve available abstracts of 69 articles: HTML format

Single Articles

March 2024
1. PANTING RG, Kotecha RS, Cheung LC
   The critical role of the bone marrow stromal microenvironment for development of drug screening platforms in leukemia.
   Exp Hematol. 2024 Mar 27:104212. doi: 10.1016/j.exphem.2024.104212.
   PubMed     Abstract available
   
   
   
2. GOSWAMI M, Bose PD
   Gut Microbial Dysbiosis in the Pathogenesis of Leukemia: An Immune-based Perspective.
   Exp Hematol. 2024 Mar 23:104211. doi: 10.1016/j.exphem.2024.104211.
   PubMed     Abstract available
   
   
   
3. LIU Q, Zhai Y, Hui Y, Chen J, et al
   Identification of Red blood cell distribution width as a prognostic factor in acute myeloid leukemia.
   Exp Hematol. 2024 Mar 18:104206. doi: 10.1016/j.exphem.2024.104206.
   PubMed     Abstract available
   
   
   February 2024
4. TANAKA T, Kudo K, Kanezaki R, Yuzawa K, et al
   Anti-leukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome.
   Exp Hematol. 2024 Feb 9:104179. doi: 10.1016/j.exphem.2024.104179.
   PubMed     Abstract available
   
   
   
5. RANDALL J, Evans K, Watts B, Kosasih HJ, et al
   IN VIVO ACTIVITY OF THE SECOND-GENERATION PROTEASOME INHIBITOR IXAZOMIB AGAINST PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS.
   Exp Hematol. 2024 Feb 4:104176. doi: 10.1016/j.exphem.2024.104176.
   PubMed     Abstract available
   
   
   
6. MERZ AMA, Platzbecker U
   Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms.
   Exp Hematol. 2024;130:104130.
   PubMed     Abstract available
   
   
   December 2023
7. ALQAZZAZ MA, Luciani GM, Vu V, Machado RM, et al
   Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
   Exp Hematol. 2023 Dec 8:S0301-472X(23)01773-3. doi: 10.1016/j.exphem.2023.
   PubMed     Abstract available
   
   
   
8. BUROCZIOVA M, Grusanovic S, Vanickova K, Kosanovic S, et al
   Chronic inflammation promotes cancer progression as a second hit.
   Exp Hematol. 2023;128:30-37.
   PubMed     Abstract available
   
   
   October 2023
9. XIE Y, Tan L, Wu K, Li D, et al
   MiR-455-3p mediates PPARalpha through UBN2 to promote apoptosis and autophagy in acute myeloid leukemia cells.
   Exp Hematol. 2023 Oct 5:S0301-472X(23)01734-4. doi: 10.1016/j.exphem.2023.
   PubMed     Abstract available
   
   
   September 2023
10. GUARNERA L, Santinelli E, Galossi E, Cristiano A, et al
    Microenvironment in Acute Myeloid Leukemia: focus on senescence mechanisms, therapeutic interactions and future directions.
    Exp Hematol. 2023 Sep 21:S0301-472X(23)01705.
    PubMed     Abstract available
    
    
    
11. HAN L, Wu J, Lyu X, Yu J, et al
    Genetic Mutation Signature for Relapse Prediction in Normal Karyotype Acute Myeloid Leukemia.
    Exp Hematol. 2023 Sep 20:S0301-472X(23)01706.
    PubMed     Abstract available
    
    
    August 2023
12. BROCCIA G, Carter J, Ozsin-Ozler C, De Matteis S, et al
    Epidemiology of chronic lymphocytic leukemia in Sardinia, Italy (1974-2003).
    Exp Hematol. 2023 Aug 9:S0301-472X(23)01669-7. doi: 10.1016/j.exphem.2023.
    PubMed     Abstract available
    
    
    
13. LIN C, Xie Y, Huang W, Lin D, et al
    Corrigendum to ' 5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9' [Volume 114, October 2022, Pages 43-53.e2].
    Exp Hematol. 2023 Aug 5:S0301-472X(23)01636-3. doi: 10.1016/j.exphem.2023.
    PubMed    
    
    
    July 2023
14. SUN Z, Lin D, Shen Y, Ma K, et al
    Critical role of MXRA7 in differentiation blockade in human acute promyelocytic leukemia cells.
    Exp Hematol. 2023 Jul 5:S0301-472X(23)00584-2. doi: 10.1016/j.exphem.2023.
    PubMed     Abstract available
    
    
    June 2023
15. ARTUS J, Zenych A, Simanic I, Desterke C, et al
    BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells.
    Exp Hematol. 2023 Jun 16:S0301-472X(23)00254.
    PubMed     Abstract available
    
    
    
16. HU H, Muntean AG
    The YEATS Domain Epigenetic Reader Proteins ENL and AF9 and Their Therapeutic Value in Leukemia.
    Exp Hematol. 2023 Jun 7:S0301-472X(23)00252-7. doi: 10.1016/j.exphem.2023.
    PubMed     Abstract available
    
    
    May 2023
17. BOILA LD, Sengupta A
    Unifying targeted therapy for leukemia in the era of PARP inhibition.
    Exp Hematol. 2023 May 24:S0301-472X(23)00228.
    PubMed     Abstract available
    
    
    
18. WILCHER KE, Page ERH, Vinnedge LMP
    The Impact of the Chromatin Binding DEK Protein in Hematopoiesis and Acute Myeloid Leukemia.
    Exp Hematol. 2023 May 10:S0301-472X(23)00225.
    PubMed     Abstract available
    
    
    April 2023
19. MAKUUCHI Y, Nakashima Y, Nishimoto M, Koh H, et al
    Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
    Exp Hematol. 2023 Apr 23:S0301-472X(23)00162.
    PubMed     Abstract available
    
    
    
20. UEDA K
    Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies.
    Exp Hematol. 2023 Apr 20:S0301-472X(23)00161.
    PubMed     Abstract available
    
    
    February 2023
21. RITTAVEE Y, Artus J, Desterke C, Simanic I, et al
    miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells.
    Exp Hematol. 2023;118:40-52.
    PubMed     Abstract available
    
    
    January 2023
22. LEE AQ, Konishi H, Helmke E, Ijiri M, et al
    Cmpd10357 to Treat B-cell Acute Lymphoblastic Leukemia.
    Exp Hematol. 2023 Jan 5:S0301-472X(22)00840-2. doi: 10.1016/j.exphem.2022.
    PubMed     Abstract available
    
    
    November 2022
23. GAO X, You X, Droin N, Banaszak LG, et al
    Role of ASXL1 in hematopoiesis and myeloid diseases.
    Exp Hematol. 2022;115:14-19.
    PubMed     Abstract available
    
    
    September 2022
24. DARBANIYAN F, Zheng H, Kanagal-Shamanna R, Lockyer P, et al
    Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
    Exp Hematol. 2022 Sep 20. pii: S0301-472X(22)00697.
    PubMed     Abstract available
    
    
    
25. PATEL SB, Kuznetsova V, Matkins VR, Franceski AM, et al
    Ex vivo expansion of phenotypic and transcriptomic CML stem cells.
    Exp Hematol. 2022 Sep 14. pii: S0301-472X(22)00696.
    PubMed     Abstract available
    
    
    
26. THAVAYOGARAJAH T, Sinitski D, Bounkari OE, Torres-Garcia L, et al
    CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.
    Exp Hematol. 2022 Sep 9. pii: S0301-472X(22)00681.
    PubMed     Abstract available
    
    
    August 2022
27. ZHOU C, Uluisik R, Rowley JW, David C, et al
    Germline ETV6 mutation promotes inflammation and disrupts lymphoid development of early hematopoietic progenitors.
    Exp Hematol. 2022;112-113:24-34.
    PubMed     Abstract available
    
    
    
28. IIDA K, Tsuchiya A, Tamura M, Yamamoto K, et al
    RUNX1 Inhibition Using Lipid Nanoparticle-Mediated Silencing RNA Delivery as an Effective Treatment for Acute Leukemias.
    Exp Hematol. 2022;112-113:1-8.
    PubMed     Abstract available
    
    
    July 2022
29. LIN C, Xu J, Li N, Li Q, et al
    5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9.
    Exp Hematol. 2022 Jul 28. pii: S0301-472X(22)00579.
    PubMed     Abstract available
    
    
    
30. CAO J, Huang S, Li X
    Rapamycin inhibits the progression of human acute myeloid leukemia by regulating circ_0094100/miR-217/ATP1B1 axis.
    Exp Hematol. 2022 Jul 25. pii: S0301-472X(22)00576.
    PubMed     Abstract available
    
    
    
31. SOMMERKAMP P, Brown JA, Haltalli MLR, Mercier FE, et al
    m(6)A RNA modifications: Key regulators of normal and malignant hematopoiesis.
    Exp Hematol. 2022;111:25-31.
    PubMed     Abstract available
    
    
    
32. UPADHYAY P, Beales J, Shah NM, Gruszczynska A, et al
    Recurrent transcriptional responses in AML and MDS patients treated with decitabine.
    Exp Hematol. 2022;111:50-65.
    PubMed     Abstract available
    
    
    June 2022
33. JUNCO JJ, Zorman B, Gant VU Jr, Munoz J, et al
    CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.
    Exp Hematol. 2022;110:34-38.
    PubMed     Abstract available
    
    
    May 2022
34. SOOF CM, Spektor TM, Parikh SA, Slager SL, et al
    Serum B-Cell Maturation Antigen is an Independent Prognostic Marker in Previously Untreated Chronic Lymphocytic Leukemia.
    Exp Hematol. 2022 May 4. pii: S0301-472X(22)00205.
    PubMed     Abstract available
    
    
    
35. KATO H, Maezawa Y, Nishijima D, Iwamoto E, et al
    A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency.
    Exp Hematol. 2022;109:11-17.
    PubMed     Abstract available
    
    
    April 2022
36. PERMATASARI HK, Nakahata S, Ichikawa T, Fauzi YR, et al
    Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma.
    Exp Hematol. 2022 Apr 11. pii: S0301-472X(22)00158.
    PubMed     Abstract available
    
    
    
37. KROPP EM, Li Q
    Mechanisms of Resistance to Targeted Therapies for Relapsed or Refractory Acute Myeloid Leukemia.
    Exp Hematol. 2022 Apr 10. pii: S0301-472X(22)00133.
    PubMed     Abstract available
    
    
    
38. REDONDO MONTE E, Leubolt G, Windisch R, Kerbs P, et al
    Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation.
    Exp Hematol. 2022;108:26-35.
    PubMed     Abstract available
    
    
    
39. KLEMPNAUER KH
    C/EBPbeta sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
    Exp Hematol. 2022;108:8-15.
    PubMed     Abstract available
    
    
    March 2022
40. GERRITSEN M, Hilgendorf S, Yi G, Wierenga ATJ, et al
    Presence of mutant p53 increases stem-cell frequency and is associated with reduced binding to classical TP53 binding sites in cell lines and primary AMLs.
    Exp Hematol. 2022 Mar 18. pii: S0301-472X(22)00128.
    PubMed     Abstract available
    
    
    
41. SHABASHVILI DE, Feng Y, Kaur P, Venugopal K, et al
    Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
    Exp Hematol. 2022 Mar 16. pii: S0301-472X(22)00125.
    PubMed     Abstract available
    
    
    
42. YAN Y, Upadhyaya R, Zhang VW, Berg T, et al
    Epigenetic Maintenance Strategies after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Exp Hematol. 2022 Mar 11. pii: S0301-472X(22)00122.
    PubMed     Abstract available
    
    
    
43. PAREDES R, Doleschall N, Connors K, Geary B, et al
    EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
    Exp Hematol. 2022;107:1-8.
    PubMed     Abstract available
    
    
    February 2022
44. CAN I, Cox MJ, Siegler EL, Kenderian SS, et al
    Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned.
    Exp Hematol. 2022 Feb 10. pii: S0301-472X(22)00069.
    PubMed     Abstract available
    
    
    
45. SIMONSEN AT, Meggendorfer M, Hansen MH, Nederby L, et al
    Acute myeloid leukemia displaying clonal instability during treatment: implications for measurable residual disease assessments.
    Exp Hematol. 2022 Feb 2. pii: S0301-472X(22)00001.
    PubMed     Abstract available
    
    
    
46. ALI A, Vaikari VP, Alachkar H
    CD99 in malignant hematopoiesis.
    Exp Hematol. 2022;106:40-46.
    PubMed    
    
    
    
47. BIGAS A, Rodriguez-Sevilla JJ, Espinosa L, Gallardo F, et al
    Recent advances in T-cell lymphoid neoplasms.
    Exp Hematol. 2022;106:3-18.
    PubMed     Abstract available
    
    
    January 2022
48. KAPADIA B, Shetty AC, Bollino D, Bhandary B, et al
    Translatome changes in acute myeloid leukemia cells post-exposure to pegcrisantaspase and venetoclax.
    Exp Hematol. 2022 Jan 29. pii: S0301-472X(22)00036.
    PubMed     Abstract available
    
    
    
49. ZHANG J, Liu X, Yin C, Zong S, et al
    hnRNPK/Beclin1 signaling regulates autophagy to promote imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
    Exp Hematol. 2022 Jan 14. pii: S0301-472X(22)00032.
    PubMed     Abstract available
    
    
    
50. LIU F, Zhao Q, Su Y, Lv J, et al
    Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Exp Hematol. 2022;105:39-49.
    PubMed     Abstract available
    
    
    December 2021
51. THURGOOD LA, Best OG, Rowland A, Lower KM, et al
    Lipid uptake in chronic lymphocytic leukemia.
    Exp Hematol. 2021 Dec 8. pii: S0301-472X(21)00624.
    PubMed     Abstract available
    
    
    
52. HE X, Zhang Y, Xu Y, Xie L, et al
    Function of the P2X7 receptor in hematopoiesis and leukemogenesis.
    Exp Hematol. 2021;104:40-47.
    PubMed     Abstract available
    
    
    November 2021
53. KENSWIL KJG, Pisterzi P, Feyen J, Ter Borg M, et al
    Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia.
    Exp Hematol. 2021 Nov 17. pii: S0301-472X(21)00426.
    PubMed     Abstract available
    
    
    
54. MA Y, Chen Z, Yu J
    Pseudogenes and their potential functions in hematopoiesis.
    Exp Hematol. 2021;103:24-29.
    PubMed     Abstract available
    
    
    September 2021
55. TREMBLAY CS, Ting SB, McCluskey A, Robinson PJ, et al
    Shutting the gate: targeting endocytosis in acute leukemia.
    Exp Hematol. 2021 Sep 23. pii: S0301-472X(21)00326.
    PubMed    
    
    
    
56. LIAO W, Eric Kohler M, Fry T, Ernst P, et al
    Corrigendum to : <[Experimental Hematology 2021; 100: 1-11]>.
    Exp Hematol. 2021 Sep 20. pii: S0301-472X(21)00293.
    PubMed    
    
    
    
57. MARIN-SANCHEZ A, Martinez-Fernandez G, Gomez-Catalan I, Montoya-Morcillo MC, et al
    Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
    Exp Hematol. 2021;101-102:49-57.
    PubMed     Abstract available
    
    
    
58. LI Y, Magee JA
    Transcriptional reprogramming in neonatal hematopoietic stem and progenitor cells.
    Exp Hematol. 2021;101-102:25-33.
    PubMed     Abstract available
    
    
    August 2021
59. LEVESQUE JP, Summers KM, Millard SM, Bisht K, et al
    Role of macrophages and phagocytes in orchestrating normal and pathologic hematopoietic niches.
    Exp Hematol. 2021;100:12-31.
    PubMed     Abstract available
    
    
    July 2021
60. HONDA A, Koya J, Yoshimi A, Miyauchi M, et al
    Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia.
    Exp Hematol. 2021 Jul 29. pii: S0301-472X(21)00280.
    PubMed     Abstract available
    
    
    
61. LIAO W, Kohler ME, Fry T, Ernst P, et al
    Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.
    Exp Hematol. 2021 Jul 21. pii: S0301-472X(21)00248.
    PubMed     Abstract available
    
    
    June 2021
62. KAEHLER M, Dworschak M, Rodin JP, Ruemenapp J, et al
    ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells.
    Exp Hematol. 2021 Jun 3. pii: S0301-472X(21)00199.
    PubMed     Abstract available
    
    
    
63. MACBETH KJ, Chopra VS, Tang L, Zheng B, et al
    Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
    Exp Hematol. 2021;98:47-52.
    PubMed     Abstract available
    
    
    May 2021
64. GRANDITS AM, Wieser R
    Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
    Exp Hematol. 2021 May 21. pii: S0301-472X(21)00195.
    PubMed     Abstract available
    
    
    
65. YOKOMIZO-NAKANO T, Sashida G
    Two faces of RUNX3 in myeloid transformation.
    Exp Hematol. 2021;97:14-20.
    PubMed     Abstract available
    
    
    
66. DI GENUA C, Nerlov C
    To bi or not to bi: Acute erythroid leukemias and hematopoietic lineage choice.
    Exp Hematol. 2021;97:6-13.
    PubMed     Abstract available
    
    
    February 2021
67. SWART LE, Heidenreich O
    The RUNX1/RUNX1T1 network: translating insights into therapeutic options.
    Exp Hematol. 2021;94:1-10.
    PubMed     Abstract available
    
    
    January 2021
68. MILONE G, Scire P, Camuglia MG, Triolo A, et al
    LOW CONTENT OF CLONOGENIC PROGENITORS ON DAY+18, IS ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND PREDICT TRANSPLANT RELATED MORTALITY.
    Exp Hematol. 2021 Jan 11. pii: S0301-472X(21)00003.
    PubMed     Abstract available
    
    
    
69. AREDE L, Pina C
    Buffering noise: KAT2A modular contributions to stabilization of transcription and cell identity in cancer and development.
    Exp Hematol. 2021;93:25-37.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.